Whole sporozoite immunization with Plasmodium falciparum strain NF135 in a randomized trial.
Malaria
NF135
Plasmodium falciparum
Vaccine-induced protection
Whole sporozoite immunization
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
07 04 2023
07 04 2023
Historique:
received:
06
09
2022
accepted:
15
02
2023
medline:
10
4
2023
entrez:
6
4
2023
pubmed:
7
4
2023
Statut:
epublish
Résumé
Whole sporozoite immunization under chemoprophylaxis (CPS regime) induces long-lasting sterile homologous protection in the controlled human malaria infection model using Plasmodium falciparum strain NF54. The relative proficiency of liver-stage parasite development may be an important factor determining immunization efficacy. Previous studies show that Plasmodium falciparum strain NF135 produces relatively high numbers of large liver-stage schizonts in vitro. Here, we evaluate this strain for use in CPS immunization regimes. In a partially randomized, open-label study conducted at the Radboudumc, Nijmegen, the Netherlands, healthy, malaria-naïve adults were immunized by three rounds of fifteen or five NF135-infected mosquito bites under mefloquine prophylaxis (cohort A) or fifteen NF135-infected mosquito bites and presumptive treatment with artemether/lumefantrine (cohort B). Cohort A participants were exposed to a homologous challenge 19 weeks after immunization. The primary objective of the study was to evaluate the safety and tolerability of CPS immunizations with NF135. Relatively high liver-to-blood inocula were observed during immunization with NF135 in both cohorts. Eighteen of 30 (60%) high-dose participants and 3/10 (30%) low-dose participants experienced grade 3 adverse events 7 to 21 days following their first immunization. All cohort A participants and two participants in cohort B developed breakthrough blood-stage malaria infections during immunizations requiring rescue treatment. The resulting compromised immunizations induced modest sterile protection against homologous challenge in cohort A (5/17; 29%). These CPS regimes using NF135 were relatively poorly tolerated and frequently required rescue treatment, thereby compromising immunization efficiency and protective efficacy. Consequently, the full potential of NF135 sporozoites for induction of immune protection remains inconclusive. Nonetheless, the high liver-stage burden achieved by this strain highlights it as an interesting potential candidate for novel whole sporozoite immunization approaches. The trial was registered at ClinicalTrials.gov under identifier NCT03813108.
Sections du résumé
BACKGROUND
Whole sporozoite immunization under chemoprophylaxis (CPS regime) induces long-lasting sterile homologous protection in the controlled human malaria infection model using Plasmodium falciparum strain NF54. The relative proficiency of liver-stage parasite development may be an important factor determining immunization efficacy. Previous studies show that Plasmodium falciparum strain NF135 produces relatively high numbers of large liver-stage schizonts in vitro. Here, we evaluate this strain for use in CPS immunization regimes.
METHODS
In a partially randomized, open-label study conducted at the Radboudumc, Nijmegen, the Netherlands, healthy, malaria-naïve adults were immunized by three rounds of fifteen or five NF135-infected mosquito bites under mefloquine prophylaxis (cohort A) or fifteen NF135-infected mosquito bites and presumptive treatment with artemether/lumefantrine (cohort B). Cohort A participants were exposed to a homologous challenge 19 weeks after immunization. The primary objective of the study was to evaluate the safety and tolerability of CPS immunizations with NF135.
RESULTS
Relatively high liver-to-blood inocula were observed during immunization with NF135 in both cohorts. Eighteen of 30 (60%) high-dose participants and 3/10 (30%) low-dose participants experienced grade 3 adverse events 7 to 21 days following their first immunization. All cohort A participants and two participants in cohort B developed breakthrough blood-stage malaria infections during immunizations requiring rescue treatment. The resulting compromised immunizations induced modest sterile protection against homologous challenge in cohort A (5/17; 29%).
CONCLUSIONS
These CPS regimes using NF135 were relatively poorly tolerated and frequently required rescue treatment, thereby compromising immunization efficiency and protective efficacy. Consequently, the full potential of NF135 sporozoites for induction of immune protection remains inconclusive. Nonetheless, the high liver-stage burden achieved by this strain highlights it as an interesting potential candidate for novel whole sporozoite immunization approaches.
TRIAL REGISTRATION
The trial was registered at ClinicalTrials.gov under identifier NCT03813108.
Identifiants
pubmed: 37024868
doi: 10.1186/s12916-023-02788-9
pii: 10.1186/s12916-023-02788-9
pmc: PMC10079489
doi:
Substances chimiques
Antimalarials
0
Artemether, Lumefantrine Drug Combination
0
Malaria Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT03813108']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Informations de copyright
© 2023. The Author(s).
Références
Nat Commun. 2021 May 4;12(1):2518
pubmed: 33947856
J Antimicrob Chemother. 2013 May;68(5):977-85
pubmed: 23292347
Nature. 2017 Feb 23;542(7642):445-449
pubmed: 28199305
BMC Med. 2017 Sep 13;15(1):168
pubmed: 28903777
Lancet. 2011 May 21;377(9779):1770-6
pubmed: 21514658
EBioMedicine. 2022 Mar;77:103919
pubmed: 35278741
Am J Trop Med Hyg. 2018 Sep;99(3):709-712
pubmed: 30014816
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447
pubmed: 15288742
J Infect Dis. 2013 Feb 15;207(4):656-60
pubmed: 23186785
JCI Insight. 2017 Jan 12;2(1):e89154
pubmed: 28097230
Nature. 2021 Jul;595(7866):289-294
pubmed: 34194041
Genome Med. 2020 Jan 8;12(1):6
pubmed: 31915075
NPJ Vaccines. 2022 Nov 4;7(1):139
pubmed: 36333336
Sci Transl Med. 2020 May 20;12(544):
pubmed: 32434847
Sci Transl Med. 2017 Jun 21;9(395):
pubmed: 28637923
Mol Biochem Parasitol. 2001 Dec;118(2):247-51
pubmed: 11738714
Science. 2013 Sep 20;341(6152):1359-65
pubmed: 23929949
Am J Trop Med Hyg. 2003 Mar;68(3):350-6
pubmed: 12685644
PLoS Pathog. 2021 May 28;17(5):e1009594
pubmed: 34048504
Parasitology. 1989 Apr;98 Pt 2:165-73
pubmed: 2668861
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
Malar J. 2009 Dec 03;8:277
pubmed: 19958549
EMBO J. 2021 Mar 15;40(6):e106583
pubmed: 33459428
Am J Trop Med Hyg. 2003 Jan;68(1):111-4
pubmed: 12556158
Am J Trop Med Hyg. 2021 Jan;104(1):283-293
pubmed: 33205741
Malar J. 2014 Jan 30;13:38
pubmed: 24479524
Clin Infect Dis. 2017 Jan 15;64(2):199-206
pubmed: 27986683
Antimicrob Agents Chemother. 2009 Dec;53(12):5069-73
pubmed: 19770282
Front Immunol. 2017 Aug 21;8:966
pubmed: 28878766
J Immunol. 2007 Sep 15;179(6):4193-201
pubmed: 17785859
Antimicrob Agents Chemother. 2005 Oct;49(10):4421-2
pubmed: 16189139
PLoS One. 2014 Nov 14;9(11):e112910
pubmed: 25396417
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7
pubmed: 23599283
J Pharm Biomed Anal. 2018 May 30;154:263-277
pubmed: 29579633
PLoS One. 2013 May 13;8(5):e64299
pubmed: 23675533